Feb 18 (Reuters) - Australian biotech CSL Ltd (CSL) on Thursday reported a 45% rise in half-year profit, boosted by higher demand for its vaccines and blood plasma products.
Net profit after tax came in at $1.81 billion for the six months ended December, up from $1.25 billion last year.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$264.31 |
Change
0.490(0.19%) |
Mkt cap ! $127.9B | |||
| Open | High | Low | Value | Volume |
| $263.30 | $265.32 | $263.02 | $149.5M | 566.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 158 | $264.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $264.31 | 221 | 1 |
View Market Depth
| Last trade - 16.19pm 12/08/2025 (20 minute delay) ? |
| CSL (ASX) Chart |